Product Images Gabapentin

This is a chart depicting mean pain scores during a study with a 4-week dose titration period followed by a 4-week fixed dose period. The chart compares the mean pain scores of a placebo group with a group taking 3600 mg/day of Gabapentin. The baseline pain score and pain scores at weeks 1 to 8 are shown on the chart.*

This is a chart related to a medication study where the dose of Gabapentin was titrated over a 3-week period and then a fixed dose was maintained for 4 weeks. There were 104 participants who either received a placebo or Gabapentin at either 1800mg/day or 2400mg/day. The chart displays the mean pain score over a duration of 7 weeks, including the baseline.*

The text describes a chart that shows the proportion of responders in controlled PHN studies at endpoint. The responders mentioned are the patients who have had more than 50% reduction in pain score. The chart consists of percentage values ranging from 0% to 100% in increments of 10. The chart describes two studies- 'Study 1' and 'Study 2'. Under study 1, 'GBP 3600' had 29% responders, 'PBO' had 12% responders. Under study 2, 'GBP 2400' had 34% responders, 'GBP 1800' had 14%, and 'PBO' had 3% responders. The text also mentions some statistical tests carried out which are not entirely discernible.*

This text provides a formula for calculating estimated creatinine clearance (CLCr) for patients using their age and serum creatinine level, with a specific adjustment factor for female patients. Not much context is given for how this calculation is to be applied or why it might be useful.*